New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study – conducted …
A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. A …
In the red-hot market for PARP inhibitors, AstraZeneca and Merck’s contender Lynparza is ahead of rival products from GlaxoSmithKline and Clovis Oncology—but not comfortably ahead. …
Adding AstraZeneca’s Lynparza to Roche’s older cancer drug Avastin helped women with advanced ovarian cancer live longer without their tumors growing, according to results from …
Amid a fresh scandal, this time over data manipulation for the world’s most expensive med, top Novartis execs laid out a detailed account Wednesday and …
Novartis’ spinal muscular atrophy gene therapy Zolgensma made all kinds of headlines leading up to and following its approval. Now, it’s making just the kind of headlines no drug …
Two months back, AstraZeneca and Merck made a strong case at the American Society of Clinical Oncology (ASCO) annual meeting that Lynparza should be the …
Roche on Monday said its immunotherapy Tecentriq helped stave off tumor growth in a Phase 3 study of previously untreated people with metastatic bladder cancer, a result …
Food and Drug Administration staff appear confident an HIV treatment developed by Gilead can also help prevent the disease from spreading, though the two parties …
Today, the U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
